Alercell develops cancer testing technology focused on very early genetic detection for cancer and leukemia. The company utilizes AI to create precise biomarkers for earlier disease identification. Their LENA Q51 product detects 51 gene mutations to advance preventative oncology diagnostics.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer diagnostics often identify disease at later stages, limiting treatment efficacy and patient outcomes. The complexity and time required for traditional testing methods can also delay critical interventions for aggressive conditions like leukemia and lung cancer.
Solution
Alercell develops advanced molecular diagnostic technologies focused on early genetic detection of cancer and leukemia. The company leverages artificial intelligence to identify precise biomarkers, enabling earlier and more accurate diagnoses. Alercell's platform aims to streamline the diagnostic process, providing actionable insights to clinicians for improved patient management and outcomes. Their approach supports the development of personalized medicine strategies by identifying specific genetic alterations associated with disease progression.
Target Audience
Alercell's primary customers are oncologists, hematologists, and diagnostic laboratories seeking advanced, rapid, and precise genetic testing solutions for early cancer and leukemia detection.
Features
- LENA Q51®: A quantitative polymerase chain reaction (qPCR) based diagnostic test that identifies 55 gene mutations for leukemia detection, delivering results in under 3 hours.
- LENA S1 Test: Utilizes DNA methylation analysis for the pre-symptomatic and precise identification of Non-Small Cell Lung Cancer (NSCLC).
- AI-driven biomarker identification: Employs machine learning algorithms to pinpoint specific genetic markers for enhanced diagnostic accuracy.
- Liquid biopsy capabilities: Offers minimally invasive sample collection for disease detection and monitoring.
- Integrated Theranostics Approach: Combines advanced diagnostics with a vision for future therapeutic integration, focusing on personalized treatment strategies.
- Comprehensive Leukemia Testing: Provides a suite of genetic tests for a detailed understanding of leukemia subtypes.